Nanobubble-Enhanced Sonobiopsy
A noninvasive platform for molecular characterization and monitoring of glioblastoma.
Molecular characterization of brain tumors currently relies on invasive surgical biopsy. Blood-based liquid biopsy offers a noninvasive alternative, but its sensitivity in brain tumors is limited by the blood-brain barrier (BBB), which restricts the release of tumor-derived biomarkers into the circulation. This limitation is particularly significant in glioblastoma (GBM), an aggressive brain cancer for which repeated molecular assessment could support diagnosis, disease monitoring and treatment-response evaluation.
OUR SOLUTION
The technology introduces a nanobubble-enhanced sonobiopsy platform for noninvasive molecular access to brain tumors. Nanobubbles approximately 180 nm in diameter circulate efficiently through cerebral capillary networks and exhibit enhanced oscillatory behavior under low-frequency focused ultrasound (FUS), enabling transient BBB opening at the capillary scale.
The platform uses BBB opening bidirectionally to facilitate the controlled release of brain- and tumor-derived biomarkers into the bloodstream. The released biomarkers can then be analyzed from a standard blood sample. Preclinical proof-of-concept demonstrated reproducible circulating protein signatures following nanobubble-mediated BBB opening in both healthy and glioblastoma-bearing mice.
Ongoing development is directed toward improving tumor-biomarker recovery and establishing a clinically translatable platform for molecular characterization, longitudinal monitoring of GBM and assessment of treatment response.
ADVANTAGES
- Noninvasive approach for accessing brain- and tumor-derived circulating biomarkers
- Nanobubble dimensions suited to the capillary-scale brain microvasculature
- Spatially and temporally controlled BBB opening using focused ultrasound
- Potential to enable repeated blood sampling for longitudinal disease monitoring
- Compatible in principle with existing clinical focused-ultrasound platforms
- Potential to complement tissue biopsy and conventional imaging
APPLICATIONS
- Molecular characterization of glioblastoma
- Enhanced detection of brain- and tumor-derived circulating biomarkers
- Longitudinal monitoring of tumor evolution and disease progression
- Assessment of treatment response and recurrence
- Biomarker discovery and translational neuroscience research
- Potential expansion to additional brain tumors and neurological diseases
DEVELOPMENT STATUS
Preclinical proof-of-concept has been demonstrated in healthy and glioblastoma-bearing mouse models. Further development will focus on validating defined GBM biomarkers, optimizing sonication and nanobubble parameters, establishing analytical sensitivity and specificity, and evaluating safety, reproducibility and clinical translation.
INTELLECTUAL PROPERTY
| PCT Application | PCT/IL2026/050486 |
| Ramot Internal Reference | P2026-0012 |
Email
Linkedin
WhatsApp
Print/PDF